The WHO recommends that trivalent vaccines for use in the 2025-2026 Northern Hemisphere season contain the following:

Egg based vaccines:

an A/Victoria/4897/2022 (H1N1)pdm09-like virus;

an A/Croatia/10136RV/2023 (H3N2)-like virus; and

a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

Cell or recombinant based vaccines:

an A/Wisconsin/67/2022 (H1N1)pdm09-like virus;

an A/District of Columbia/27/2023 (H3N2)-like virus; and

a B/Austria/1359417/2021 (B/Victoria lineage)-like virus .

For quadrivalent egg- or cell culture-based or recombinant vaccines for use in the 2025-2026 northern hemisphere influenza season: While the B/Yamagata lineage vaccine component should be excluded as it is no longer warranted, where quadrivalent vaccines are still in use, the B/Yamagata lineage component remains unchanged:

Egg-, cell- or recombinant-based Vaccines

a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

Full WHO Recommendation

Top of Page

The AIVC met in October 2024 and recommended that the following viruses be used for influenza vaccines in the 2025 Southern Hemisphere influenza season:

Egg based trivalent influenza vaccines:

an A/Victoria/4897/2022 (H1N1)pdm09-like virus;

an A/Croatia/10136RV/2023 (H3N2)-like virus; and

a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

Cell-based trivalent influenza vaccines:

an an A/Wisconsin/67/2022 (H1N1)pdm09-like virus;

a an A//District of Columbia/27/2023 (H3N2)-like virus; and

a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

The recommendation for the B/Yamagata lineage component of quadrivalent influenza vaccines remains unchanged from previous recommendations:

a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

See the TGA website for further information

Top of Page

The WHO recommends that trivalent vaccines for use in the 2025 Southern Hemisphere season contain the following:

Egg-based vaccines:

an A/Victoria/4897/2022 (H1N1)pdm09-like virus

an A/Croatia/10136RV/2023 (H3N2)-like virus; and

a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

Cell culture-, recombinant protein- or nucleic acid-based vaccines

an A/Wisconsin/67/2022 (H1N1)pdm09-like virus;

an A/District of Columbia/27/2023 (H3N2)-like virus; and

a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

The recommendation for the B/Yamagata lineage component of quadrivalent influenza vaccines remains unchanged from previous recommendations

a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus

Full WHO Recommendation

Top of Page

The WHO recommends that trivalent vaccines for use in the 2024-2025 Northern Hemisphere season contain the following:

Egg based vaccines:

an A/Victoria/4897/2022 (H1N1)pdm09-like virus;

an A/Thailand/8/2022 (H3N2)-like virus; and

a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

Cell or recombinant based vaccines:

an A/Wisconsin/67/2022 (H1N1)pdm09-like virus;

a an A/Massachusetts/18/2022 (H3N2)-like virus; and

a B/Austria/1359417/2021 (B/Victoria lineage)-like virus .

For quadrivalent egg- or cell culture-based or recombinant vaccines for use in the 2024-2025 northern hemisphere influenza season: While the B/Yamagata lineage vaccine component should be excluded as it is no longer warranted, where quadrivalent vaccines are still in use, the B/Yamagata lineage component remains unchanged:

Egg-, cell- or recombinant-based Vaccines

a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

Full WHO Recommendation

Top of Page

The AIVC met in October 2023 and recommended that the following viruses be used for influenza vaccines in the 2024 Southern Hemisphere influenza season:

Egg based quadrivalent influenza vaccines:

an A/Victoria/4897/2022 (H1N1)pdm09-like virus;

an A/Thailand/8/2022 (H3N2)-like virus; and

a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

Cell or recombinant based quadrivalent influenza vaccines:

an an A/Wisconsin/67/2022 (H1N1)pdm09-like virus;

a an A/Massachusetts/18/2022 (H3N2)-like virus; and

a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

The recommendation for the B/Yamagata lineage component of quadrivalent influenza vaccines remains unchanged from previous recommendations:

a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

See the TGA website for further information

Top of Page

It is recommended that trivalent vaccines for use in the 2024 Southern Hemisphere influenza season contain the following: :

Egg based vaccines:

an A/Victoria/4897/2022 (H1N1)pdm09-like virus;

an A/Thailand/8/2022 (H3N2)-like virus; and

a B/Austria/1359417/2021 (B/Victoria lineage)-like virus..

Cell or recombinant based vaccines:

an A/Wisconsin/67/2022 (H1N1)pdm09-like virus;

an A/Massachusetts/18/2022 (H3N2)-like virus; and

a B/Austria/1359417/2021 (B/Victoria lineage)-like virus..

For quadrivalent egg or cell culture-based or recombinant vaccines for use in 2024 southern hemisphere influenza season, the WHO recommends inclusion of the following B/Yamagata lineage component: :

a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

Full WHO Recommendation

Top of Page